journal article·2019-12-04Open access

Protective effect of ginsenoside Rg1 on attenuating anti-GBM glomerular nephritis by activating NRF2 signalling

Xiaojuan Guo, Jingyuan Zhang, Min Liu, Guo Chen Zhao

Abstract

Background/Aim: Ginsenoside Rg1 exerts a beneficial effect in many kidney diseases. But little work has been done to confirm whether ginsenoside Rg1 could also exert a protective effect on anti-glomerular basement membrane (anti-GBM) glomerular nephritis (GN). We aimed to explore the role of ginsenoside Rg1 in attenuating anti-GBM GN in vitro and in vivo and investigate the mechanism under its action.Methods: Interleukin-1β (IL-1β) treated podocytes were used as a cell model. A total of 20 mice were used to build the Anti-GBM GN mice model. Real-time PCR analysis (RT-PCR), Western blot analysis and ELISA assay were conducted to detect related indicators in this study. The statistical analysis was performed using GraphPad Prism software 6.0.Results: Ginsenoside Rg1 attenuates IL-1β-induced inflammation and apoptosis in podocytes. NRF2 expression can be inhibited by IL-1β, whereas reversed by ginsenoside Rg1. NRF2 inhibitor ML385 can significantly reverse the effects of ginsenoside Rg1 on inflammation and apoptosis induced by IL-1β, and block the inhibitory effect of ginsenoside Rg1 on IL-1β activated MAPK pathway. In addition, ginsenoside Rg1 could improve anti-GBM GN injury in vivo.Conclusion: Ginsenoside Rg1 inhibits the anti-GBM GN damage through regulating NRF2 pathway in vitro and in vivo. Our findings provide new insight and mechanism of ginsenoside Rg1 to prevent anti-GBM GN.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Ginseng Biological Effects and Applications · Genomics, phytochemicals, and oxidative stress · Pharmacological Effects of Natural Compounds

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Kidney, School of Clinical Medicine, Nanjing University of Traditional Chinese Medicine

Department of Kidney, Nanjing boda kidney hospital affiliated to Nan Jing University Chinese Medicine

References (28)

Show source-provided references
1. Wieliczko M, Dylewska M.iga nephropathy-prognostic factors and treatment. Wiad Lek. 2016;69:707–710.
2. 10.1016/j.jaut.2017.12.00510.1016/j.jaut.2017.12.005 ↗
3. 10.1007/s10157-016-1371-810.1007/s10157-016-1371-8 ↗
4. 10.1007/s00292-018-0475-110.1007/s00292-018-0475-1 ↗
5. 10.2215/CJN.0192021810.2215/CJN.01920218 ↗
6. 10.1556/650.2017.3092410.1556/650.2017.30924 ↗
7. Arranz O, Ara J, Rodriguez R, et al. rapid-detection GBM-ANCA Elisa. An emergency tool for the early diagnosis of type I and II rapidly progressive glomerulonephritis. Nefrologia 2001;21:349–354.
8. Suzuki Y, Yamada H, Ito M. antinephritic effect of md-805 [(2r, 4r)-4-methyl-[n2-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-l-arginyl]-2-piperidine-carboxylic acid monohydrate], a new antithrombin agent, on crescentic-type anti-GBM nephritis in rats. Nihon Jinzo Gakkai Shi. 1984;26:463–473.
9. 10.1007/s10157-019-01701-010.1007/s10157-019-01701-0 ↗
10. 10.1016/j.jgr.2013.11.00110.1016/j.jgr.2013.11.001 ↗
11. 10.1159/00004611610.1159/000046116 ↗
12. 10.1016/j.jss.2016.08.08010.1016/j.jss.2016.08.080 ↗
13. 10.1038/srep3848010.1038/srep38480 ↗
14. El Nakeeb N, Saleh SA, Massoud YM, et al. Serum ferritin as a non-invasive marker in the prediction of hepatic fibrosis among egyptian patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2017;1:112–119.
15. 10.2215/CJN.0138021710.2215/CJN.01380217 ↗
16. 10.1038/s41467-018-03181-410.1038/s41467-018-03181-4 ↗
17. 10.1038/ki.2013.44810.1038/ki.2013.448 ↗
18. 10.1007/s40620-013-0020-510.1007/s40620-013-0020-5 ↗
19. 10.1159/00034846010.1159/000348460 ↗
20. 10.1002/art.3794010.1002/art.37940 ↗
21. 10.1016/j.jep.2011.12.00910.1016/j.jep.2011.12.009 ↗
22. 10.1002/ptr.319010.1002/ptr.3190 ↗
23. 10.3109/13880209.2015.112954310.3109/13880209.2015.1129543 ↗
24. 10.1038/aps.2013.18710.1038/aps.2013.187 ↗
25. 10.1038/labinvest.2011.6110.1038/labinvest.2011.61 ↗
26. 10.1186/s13075-016-1039-510.1186/s13075-016-1039-5 ↗
27. 10.1016/j.molimm.2015.06.02510.1016/j.molimm.2015.06.025 ↗
28. 10.1016/j.freeradbiomed.2015.01.00810.1016/j.freeradbiomed.2015.01.008 ↗